Cardiac Repolarization
6
1
1
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.7%
1 terminated out of 6 trials
80.0%
-6.5% vs benchmark
17%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects
Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects
Droperidol and Cardiac Repolarization
Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects